Mycoplasma Arthritis

Mycoplasma arthritis is an important infectious cause of lameness in growing and finishing swine, caused primarily by Mycoplasma hyosynoviae, a small bacterium that colonizes the upper respiratory tract and tonsils before occasionally invading the bloodstream and localizing to joints where it causes acute non-suppurative arthritis. This condition represents one of the most common infectious causes of lameness in commercial swine operations, with affected pigs developing sudden-onset lameness that can range from mild stiffness to complete inability to bear weight on affected limbs. The disease primarily affects pigs in the late nursery through finishing phases, with peak incidence occurring between twelve and twenty-four weeks of age, though animals outside this age range may occasionally be affected.

Mycoplasma hyosynoviae differs from conventional bacteria in lacking a cell wall, which confers intrinsic resistance to beta-lactam antibiotics including penicillins and cephalosporins that target cell wall synthesis. This unique structural characteristic also makes the organism fragile in the environment, surviving only briefly outside the host, and creates challenges for laboratory diagnosis because the organism requires specialized media and extended incubation times for successful culture. The tonsillar colonization that precedes systemic invasion is extremely common in swine populations, with most commercial herds harboring the organism without experiencing clinical disease problems, indicating that additional factors beyond simple infection are required for arthritis development.

The economic impact of mycoplasma arthritis includes direct losses from mortality in severely affected animals, reduced growth rates in pigs experiencing chronic lameness, increased feed costs per pound of gain due to reduced efficiency, and market penalties for animals with visible lameness or joint lesions at slaughter. Studies estimate that clinically lame pigs may gain twenty to thirty percent less efficiently than sound pen mates during recovery periods, translating to significant economic losses when disease affects substantial proportions of finishing populations. Additionally, severely lame animals may be culled before reaching market weight, representing complete loss of the investment in those individuals from birth through disease onset.

Successful management of mycoplasma arthritis requires understanding the complex interplay between ubiquitous bacterial colonization and the occasional development of clinical disease, recognizing that elimination of Mycoplasma hyosynoviae from swine populations is neither practical nor necessary for disease control. Instead, management efforts focus on minimizing stressors that trigger disease expression, ensuring prompt treatment of affected individuals, and optimizing environmental and husbandry conditions that influence disease severity when outbreaks occur.

Mycoplasma hyosynoviae, the primary causative agent of mycoplasma arthritis in swine, is a member of the Mollicutes class of bacteria characterized by absence of a rigid cell wall, small genome size, and dependence on host tissues for many nutrients that free-living bacteria synthesize independently. The organism colonizes the tonsillar crypts and upper respiratory tract of pigs, establishing persistent carriage that may last for months without causing clinical disease in most infected individuals. Multiple strains of varying virulence exist within the species, though strain-level differences in disease-causing potential remain incompletely characterized despite their apparent importance in determining outbreak severity.

Transmission of Mycoplasma hyosynoviae occurs through direct contact between infected and susceptible pigs, with respiratory secretions and nose-to-nose contact serving as the primary routes of bacterial spread. Colonized sows transmit the organism to nursing piglets, though clinical disease at this young age is uncommon due to passive protection from maternal antibodies. As maternal immunity wanes during the growing period, pigs become increasingly susceptible to the systemic invasion that produces clinical arthritis, explaining the characteristic age distribution of disease affecting late-nursery and finishing pigs rather than younger animals.

The pathogenesis of mycoplasma arthritis involves hematogenous spread of bacteria from the tonsillar colonization site to synovial membranes of joints, where the organisms attach to articular surfaces and trigger inflammatory responses that produce the clinical signs and joint damage associated with disease. The transition from asymptomatic tonsillar carriage to systemic invasion and joint localization depends on complex interactions between bacterial factors, host immune status, and environmental or management conditions that remain only partially understood. Not all colonized pigs develop arthritis, and identifying the specific triggers that determine which individuals progress from colonization to clinical disease remains an active area of research.

Stress represents the most consistently identified risk factor for triggering clinical mycoplasma arthritis in pigs harboring tonsillar colonization. Transportation stress, mixing of unfamiliar animals, overcrowding, temperature extremes, feed or water deprivation, and concurrent infections all increase the likelihood of disease expression in colonized populations. The immunomodulatory effects of stress hormones may compromise local immune defenses that normally contain the organism at the tonsillar colonization site, allowing bacterial access to the bloodstream and subsequent joint localization.

Co-infections with other respiratory and systemic pathogens frequently precede or accompany mycoplasma arthritis outbreaks, suggesting synergistic interactions that enhance disease expression. Porcine reproductive and respiratory syndrome virus, swine influenza virus, and porcine circovirus type 2 all cause immunosuppression that may facilitate Mycoplasma hyosynoviae systemic invasion. Concurrent bacterial infections including Streptococcus suis, Haemophilus parasuis, and other pyogenic organisms may produce mixed-etiology arthritis that is more severe than mycoplasma infection alone.

Clinical signs of mycoplasma arthritis typically appear suddenly, with affected pigs developing acute lameness that may involve one or multiple limbs without preceding signs of systemic illness in most cases. The onset is often so abrupt that producers report animals appearing completely normal at one observation and severely lame just hours later, with the lameness sometimes progressing rapidly from mild stiffness to complete non-weight-bearing within a single day. Unlike many infectious arthritis conditions, mycoplasma arthritis characteristically occurs without accompanying fever, depression, or appetite loss during the early disease stages, making the sudden appearance of severe lameness in an otherwise apparently healthy pig quite distinctive.

Lameness severity varies considerably between individuals and may range from subtle gait abnormalities detectable only by careful observation to complete inability to bear weight on affected limbs. Mildly affected pigs show shortened stride length, reluctance to make sharp turns, and preference for lying down rather than standing, but continue to rise for feeding and can move about the pen when necessary. Moderately affected animals demonstrate obvious limping, uneven weight distribution, and difficulty navigating obstacles such as feeders or pen divisions, while severely affected pigs may be completely unable to rise and remain in lateral or sternal recumbency unless physically assisted to their feet.

Joint swelling is often less prominent than might be expected given the severity of lameness, distinguishing mycoplasma arthritis from some other infectious arthritis conditions that produce dramatic periarticular swelling. Affected joints may show slight effusion and increased warmth but rarely develop the tense, fluctuant swelling characteristic of suppurative bacterial arthritis. Multiple joints are typically involved, with the carpus, tarsus, elbow, stifle, and hip being most commonly affected, though essentially any synovial structure including the small joints of the feet may develop infection. The pattern of multiple joint involvement combined with relatively mild visible swelling provides useful diagnostic clues when evaluating lame finishing pigs.

Behavioral changes accompanying lameness include reduced competitive ability at feeders, increased time spent lying down, reluctance to interact with pen mates, and in group-housed animals, tendency to position near walls or in corners where less mobile individuals can avoid trampling by more active cohorts. Affected pigs often adopt characteristic postures that minimize weight-bearing on painful joints, such as standing with limbs gathered under the body, shifting weight frequently between legs, or sitting in a dog-like position when hindlimb joints are primarily affected. These behavioral adaptations help affected animals cope with pain but also contribute to reduced feed intake and growth rate during the disease period.

The clinical course of untreated mycoplasma arthritis typically involves gradual improvement over two to six weeks as the host immune response eventually controls the infection, though some animals develop chronic lameness that persists for months or becomes permanent due to joint damage sustained during the acute phase. Early treatment significantly shortens the disease duration and reduces the likelihood of chronic sequelae, making prompt recognition and intervention economically important for minimizing production losses. Animals that remain untreated or respond poorly to therapy may develop joint ankylosis, chronic synovitis, or degenerative joint disease that renders them permanently lame.

Multiple animals within a group or barn are often affected over a period of days to weeks during outbreaks, though the sporadic nature of disease expression means that severe epidemics affecting large proportions of populations are uncommon. The clustering of cases following stress events such as movement, mixing, or environmental challenges provides epidemiological clues supporting a mycoplasma arthritis diagnosis. Mortality directly from mycoplasma arthritis is uncommon unless severely affected animals are unable to access feed and water, though culling of chronically lame pigs that fail to recover adequately represents an indirect mortality outcome of the disease.

Diagnosis of mycoplasma arthritis relies on recognition of characteristic clinical presentation combined with laboratory confirmation of Mycoplasma hyosynoviae involvement in affected joints, as the clinical signs alone, while suggestive, overlap with other causes of polyarthritis in finishing pigs. The combination of sudden-onset polyarthritis without fever or systemic illness in pigs of appropriate age strongly suggests mycoplasma infection, particularly when cases cluster following identified stress events, but definitive diagnosis requires demonstration of the organism in synovial samples from affected animals.

Joint fluid collection for diagnostic testing should be performed aseptically from visibly affected joints before initiating antimicrobial therapy when possible, as treatment dramatically reduces the likelihood of successful organism detection. Normal porcine synovial fluid is clear, pale yellow, and viscous, while fluid from mycoplasma-affected joints typically shows increased volume, reduced viscosity, and mild turbidity due to inflammatory cell infiltration. Cell counts reveal moderate mononuclear cell predominance, distinguishing mycoplasma arthritis from suppurative bacterial infections that produce neutrophil-dominated inflammatory infiltrates with much higher total cell counts.

Polymerase chain reaction testing has become the preferred diagnostic method for confirming Mycoplasma hyosynoviae involvement due to superior sensitivity compared to culture and faster turnaround time. PCR detects mycoplasmal DNA in synovial fluid, joint tissue, or tonsillar samples and can provide results within days compared to the one to three weeks required for successful culture. However, positive PCR results from tonsillar samples merely confirm colonization rather than causation of arthritis, making synovial fluid testing more diagnostically relevant for establishing the organism's role in observed lameness.

Culture of Mycoplasma hyosynoviae from clinical samples remains challenging due to the organism's fastidious growth requirements and slow replication time. Specialized mycoplasma media supplemented with serum and other growth factors are required, and plates must be incubated for extended periods under microaerophilic conditions before colonies become visible. Many diagnostic laboratories offer mycoplasma culture, but the technical demands and prolonged incubation times make culture results less useful for guiding immediate treatment decisions compared to faster molecular methods.

Differential diagnosis for polyarthritis in finishing pigs includes other infectious causes such as Streptococcus suis, erysipelas, Haemophilus parasuis, and Mycoplasma hyorhinis, as well as non-infectious conditions including osteochondrosis and traumatic joint injury. Clinical features, joint fluid characteristics, and response to specific antimicrobial therapy help distinguish between these possibilities when laboratory confirmation is unavailable or delayed. The characteristic absence of fever and systemic illness in mycoplasma arthritis contrasts with the septicemic presentation of streptococcal or Haemophilus infections, providing useful clinical differentiation.

Treatment of mycoplasma arthritis requires selection of antimicrobials that effectively penetrate synovial tissues and have activity against cell-wall-deficient organisms, as the lack of a cell wall in mycoplasmas renders beta-lactam antibiotics completely ineffective regardless of dose or duration. Lincosamides, particularly lincomycin and its derivatives, represent the antimicrobial class most commonly employed for mycoplasma arthritis treatment due to good in vitro activity against Mycoplasma hyosynoviae combined with favorable tissue distribution including synovial penetration. Tiamulin and other pleuromutilins also demonstrate excellent mycoplasma activity and represent valuable alternatives when lincosamide resistance is suspected or when regulatory considerations favor different drug classes.

Individual treatment of clinically affected pigs with injectable antimicrobials provides the most reliable drug delivery for severely lame animals that may have reduced feed and water intake compromising the effectiveness of oral or in-feed medication. Initial injectable therapy with lincomycin, tiamulin, or similar active agents administered according to labeled dosing instructions typically produces clinical improvement within two to four days, with most responsive animals showing reduced lameness severity by the third day of treatment. Extended treatment courses of five to seven days are generally recommended to ensure adequate bacterial suppression and reduce relapse risk compared to shorter treatment durations.

Mass medication of pen mates and other at-risk groups may be warranted during outbreaks when multiple cases suggest ongoing transmission and additional animals are likely to develop clinical disease. Water medication with appropriate antimicrobials provides convenient treatment delivery for large groups of pigs, though variable water intake during the immediate post-stress period when disease risk peaks may limit effectiveness. In-feed medication offers more consistent intake for extended treatment or prevention periods but requires several days to achieve therapeutic tissue concentrations, making it better suited for ongoing suppression than acute outbreak response.

Anti-inflammatory therapy provides valuable adjunctive support by reducing joint inflammation and associated pain, improving mobility and maintaining feed intake during the treatment period. Non-steroidal anti-inflammatory drugs including meloxicam, flunixin meglumine, and ketoprofen all demonstrate efficacy for reducing lameness severity and improving animal welfare during acute mycoplasma arthritis episodes. Some practitioners initiate anti-inflammatory therapy concurrently with antimicrobials for all clinically affected animals, while others reserve anti-inflammatory use for the most severely lame individuals.

Supportive care measures complement antimicrobial and anti-inflammatory therapy by reducing additional stressors and supporting recovery in affected animals. Providing affected pigs with comfortable, non-slip bedding reduces further joint trauma and makes rising and movement less difficult. Ensuring easy access to feed and water by positioning resources close to where lame animals rest helps maintain intake despite reduced mobility. Separation from aggressive pen mates may be necessary for severely affected individuals unable to compete effectively for resources or defend themselves from bullying behaviors.

Withdrawal time compliance is mandatory when treating market-weight finishing pigs, as many antimicrobials effective against mycoplasmas have extended elimination periods from edible tissues. Producers must maintain accurate treatment records documenting products used, dosages administered, individual animals treated, and calculated withdrawal dates to ensure that no treated animal enters the food supply before appropriate clearance periods have elapsed. Economic considerations may influence treatment decisions for animals approaching market weight, as the combination of treatment costs, withdrawal time delays, and reduced growth performance during recovery may exceed the animal's market value in some circumstances.

Recovery from mycoplasma arthritis follows a typical timeline of initial clinical improvement within two to four days of effective treatment initiation, followed by gradual resolution of lameness over one to three weeks depending on disease severity and extent of joint involvement at treatment onset. Pigs that receive early treatment when lameness is still mild typically recover most completely, often returning to normal gait and growth performance within two weeks of treatment completion. Conversely, animals with severe lameness, multiple affected joints, or delayed treatment initiation face prolonged recovery periods and higher risk of permanent joint damage that prevents complete resolution.

Post-treatment monitoring should assess response to therapy and identify animals requiring extended treatment, alternative antimicrobials, or additional supportive care to optimize outcomes. Continued lameness beyond one week of appropriate treatment suggests treatment failure, concurrent infection with resistant organisms, or structural joint damage that will not resolve with antimicrobial therapy alone. These poorly responding animals warrant reevaluation including possible joint fluid sampling for culture and sensitivity testing to guide alternative treatment selection.

Prognosis for individual animals depends significantly on disease severity at treatment initiation and the extent of joint damage sustained before effective bacterial control is achieved. Most pigs with acute mycoplasma arthritis that receive appropriate early treatment recover fully without long-term sequelae, eventually achieving market weight with only modest growth delays attributable to the disease episode. However, animals that develop severe joint damage, particularly those with fibrin deposition, cartilage erosion, or synovial proliferation observed at necropsy of fatal cases or assumed based on clinical progression, face guarded prognosis for complete recovery.

Return to production for recovered animals involves gradual resumption of normal activity levels as lameness resolves, with most pigs naturally increasing movement and competitive feeding behavior as joint pain diminishes. Growth rates typically rebound following recovery, though animals that experienced prolonged disease courses may never fully compensate for growth lost during the acute and recovery phases, arriving at market weight somewhat later than unaffected cohorts. Breeding animals that recover from mycoplasma arthritis generally experience no long-term effects on reproductive function, though residual joint damage may limit the breeding careers of animals requiring extensive locomotion for mating activities.

Prevention of mycoplasma arthritis focuses on minimizing stress factors that trigger clinical disease expression in colonized populations rather than attempting to eliminate Mycoplasma hyosynoviae from swine herds, as the organism's ubiquitous presence and efficient transmission make eradication impractical for most commercial operations. Stress reduction strategies include optimizing animal flow to minimize mixing events, providing adequate space and environmental conditions that support animal comfort, and managing concurrent disease challenges that may compound stress effects and enhance mycoplasma disease expression.

All-in-all-out production flow, where all pigs in a barn or room are moved as cohesive groups without mixing with animals from other sources, reduces both stress and pathogen transmission compared to continuous flow systems that repeatedly introduce unfamiliar animals and associated social disruption. When mixing cannot be avoided, minimizing the number of sources from which pigs are combined and ensuring health status compatibility between groups helps reduce disease challenges during the high-risk post-mixing period. Timing movement and mixing events to avoid coinciding with other stressors such as vaccination, dietary changes, or environmental challenges further reduces cumulative stress loads.

Environmental management that maintains animal comfort reduces stress contributions to disease expression and supports immune function during periods when mycoplasma arthritis risk is elevated. Temperature control within the thermoneutral zone for the age and body weight of housed animals, appropriate ventilation that ensures adequate air quality without creating drafts, and stocking densities that allow comfortable resting and feeding without excessive competition all contribute to reduced stress and improved disease resistance.

Vaccination against Mycoplasma hyosynoviae using commercial or autogenous bacterins has been employed in some herds with recurrent problems, though variable efficacy results have limited widespread adoption of vaccination as a primary control strategy. The immunological complexity of mycoplasma infections and the persistence of organisms despite apparent immune responses create challenges for developing consistently effective vaccines. Autogenous vaccines prepared from isolates obtained from clinically affected pigs in specific herds may provide better protection than commercial products for operations with well-characterized strain populations.

Strategic antimicrobial medication during identified high-risk periods may reduce mycoplasma arthritis incidence in herds with recurrent problems despite optimization of management factors. Pulse medication with lincomycin or tiamulin in water or feed during the two to three weeks following stressful events such as movement or mixing provides prophylactic protection during the period of highest disease risk. However, concerns about antimicrobial stewardship and potential resistance selection argue against routine prophylactic use in herds where management optimization alone adequately controls disease incidence.

Daily management of finishing facilities where mycoplasma arthritis occurs or represents an ongoing concern requires systematic observation for early lameness detection combined with prompt treatment response that optimizes individual animal outcomes and limits disease spread within affected populations. Observational protocols should include assessment of gait in all animals, noting any reluctance to rise, abnormal postures, or uneven weight distribution that might indicate developing joint problems. Early detection and treatment dramatically improve prognosis compared to delayed intervention after severe joint damage has already occurred.

Housing and environmental management should prioritize animal comfort through appropriate flooring, adequate space allocation, and environmental conditions that minimize stress on the musculoskeletal system. Non-slip flooring reduces traumatic joint injury and allows lame animals to move more confidently, while adequate bedding provides cushioning that reduces pressure on affected joints during recumbency. Avoiding abrupt changes in flooring surface between areas helps prevent slipping injuries that might compound existing lameness or create conditions favoring joint infection.

Herd health programs should establish clear protocols for lameness identification, treatment initiation, and veterinary communication that empower barn staff to respond appropriately without awaiting confirmation of every case. Written treatment protocols specifying antimicrobial selection, dosing, duration, and withdrawal time documentation requirements ensure consistent appropriate therapy regardless of which staff members identify and treat affected animals. Regular communication between farm personnel and veterinary advisors enables protocol refinement based on treatment outcomes and emerging disease patterns.

Record keeping supports effective mycoplasma arthritis management by documenting incidence patterns, treatment responses, and associations between disease occurrence and management events that might inform prevention strategies. Lameness records should note affected animals, joints involved, treatment provided, and outcome assessment at defined follow-up intervals. Analyzing these records over time may reveal associations with specific stress events, environmental conditions, or pig sources that suggest targeted intervention opportunities.

Economic management of mycoplasma arthritis balances treatment costs against production losses from untreated or inadequately treated animals, considering both immediate expenses and longer-term impacts on growth performance and market timing. Cost-benefit analysis of prevention investments including facility modifications, management practice changes, and strategic medication programs helps guide resource allocation toward interventions likely to provide positive returns through reduced disease impact. Benchmarking disease incidence and associated losses against industry standards and historical farm performance helps identify operations where control efforts should be intensified or successful programs that might serve as models for other facilities.

All commercial swine breeds demonstrate susceptibility to mycoplasma arthritis when exposed to virulent Mycoplasma hyosynoviae strains under conditions favoring disease expression, with no evidence that genetic selection has produced breeds with meaningful resistance to this infection. Yorkshire, Landrace, Duroc, Hampshire, and other foundation breeds all develop characteristic arthritis following systemic mycoplasma infection, reflecting the conserved nature of synovial tissue responses to bacterial invasion across pig genetic backgrounds. Crossbred finishing pigs, which comprise the majority of commercial swine populations, show no enhanced or reduced susceptibility compared to their purebred parent populations.

Certain conformation characteristics associated with modern high-production genetics may indirectly influence mycoplasma arthritis risk by affecting joint stress patterns and predisposition to concurrent musculoskeletal conditions. Heavy-muscled terminal sire lines selected for rapid lean gain may place increased mechanical loads on joints that could theoretically enhance inflammation following mycoplasma infection, though direct evidence linking specific genetic lines to increased mycoplasma arthritis susceptibility remains limited. Similarly, structural leg weakness associated with some genetic lines might compound the impact of joint infection, even if initial infection susceptibility is equivalent.

Genetic selection for resistance to mycoplasma arthritis has not been systematically pursued in commercial breeding programs due to the complex, multifactorial nature of disease expression that makes resistant phenotypes difficult to identify and select for. The ubiquity of Mycoplasma hyosynoviae colonization combined with the sporadic occurrence of clinical disease creates challenges for developing selection strategies based on disease phenotypes, as most colonized animals never develop arthritis regardless of genetic background. Research into genetic markers associated with immune response variation might eventually enable indirect selection for enhanced mycoplasma resistance, but practical application of such approaches remains distant.

Several other infectious causes of polyarthritis in swine must be differentiated from mycoplasma arthritis when evaluating lame finishing pigs, as treatment approaches and prognosis vary between etiologies. Erysipelas, caused by Erysipelothrix rhusiopathiae, produces acute polyarthritis with fever and characteristic diamond-shaped skin lesions that help distinguish it from the afebrile presentation of mycoplasma infection. Streptococcus suis causes septicemic arthritis often accompanied by meningitis and fever, with joint fluid showing suppurative inflammation rather than the mononuclear infiltrate characteristic of mycoplasmal disease.

Mycoplasma hyorhinis represents another mycoplasmal cause of polyarthritis and polyserositis in swine, typically affecting younger pigs in the three to ten week age range compared to the older finishing pigs most commonly affected by Mycoplasma hyosynoviae. The two mycoplasma species produce clinically similar joint disease and respond to the same antimicrobial classes, making precise species identification less critical for treatment decisions but important for understanding herd epidemiology and developing targeted prevention strategies. Laboratory differentiation requires species-specific PCR or culture with biochemical identification.

Osteochondrosis represents an important non-infectious cause of lameness in growing and finishing pigs that may occur concurrently with or be confused with mycoplasma arthritis. This developmental abnormality of cartilage growth produces joint lesions and lameness that does not respond to antimicrobial therapy, helping distinguish it from infectious causes when treatment trials are employed diagnostically. Genetic predisposition, rapid growth rate, and nutritional factors influence osteochondrosis development, and the condition may predispose affected joints to secondary infection by creating tissue abnormalities that favor bacterial localization.